The homocamptothecin BN 80915 is a highly potent orally active topoisomerase I poison

Anti-Cancer Drugs

Volumn 12, Issue 1, 2001, Pages 9-19

  Demarquay, D ^a   Huchet, M ^a   Coulomb, H ^a   Lesueur Ginot, L ^a   Lavergne, O ^a   Kasprzyk, P G ^a   Bailly, C ^a   Camara, J ^a   Bigg, D Ch ^a  

^a Institut Henri Beaufour   (France)

Author keywords

Cell proliferation; Homocamptothecin; MDR; Topoisomerase I inhibitor; Xenograft

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; ALPHA HYDROXYLACTONE; BETA HYDROXYLACTONE; BSN 80915; CAMPTOTHECIN DERIVATIVE; DIFLOMOTECAN; DIFLUOROHOMOCAMPTOTHECIN; DNA TOPOISOMERASE; GLYCOPROTEIN P; HOMOCAMPTOTHECIN; IRINOTECAN; LACTONE DERIVATIVE; MEPACRINE; MULTIDRUG RESISTANCE PROTEIN; TOPOTECAN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GROWTH; CELL FREE SYSTEM; CELL PROLIFERATION; COLORECTAL CARCINOMA; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACCUMULATION; DRUG EFFICACY; DRUG POTENCY; ENZYME ACTIVITY; HUMAN; HUMAN CELL; HYDROLYSIS; IC 50; NEPHROTOXICITY; PRIORITY JOURNAL; URINARY EXCRETION;

ADENOCARCINOMA; ADMINISTRATION, ORAL; ANIMALS; ANTINEOPLASTIC AGENTS; CAMPTOTHECIN; CELL DIVISION; CELL-FREE SYSTEM; DNA; DNA TOPOISOMERASES, TYPE I; DRUG SCREENING ASSAYS, ANTITUMOR; DRUG STABILITY; ENZYME INHIBITORS; FEMALE; HUMANS; MALE; MICE; MICE, NUDE; OSTEONECTIN; PROSTATIC NEOPLASMS; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 0035122238     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-200101000-00003     Document Type: Article

References (42)

1. DNA topoisomerase I: Customs officer at the border between DNA and RNA worlds?
2. Topoisomerase enzymes as drug targets
3. Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I
4. The other camptothecins: Recent advances with camptothecin analogues other than irinotecan and topotecan
5. Topoisomerase I inhibitors: Review and update
6. Setting a new standard - Irinotecan (Campto) in the second-line therapy of colorectal cancer: Final results of two phase III studies and implications for clinical practice
7. Camptothecin antitumor agents
8. 10th Conference on DNA Topoisomerases in Therapy
9. A phase I clinical and pharmacological study of oral 9-nitrocamptothecin, a novel water-insoluble topoisomerase I inhibitor
10. Phase I and pharmacokinetic trial of oral irinotecan administered daily for 5 days every 3 weeks in patients with solid tumors
11. The evolving role of oral topotecan
12. Oral topoisomerase 1 inhibitors in adult patients: Present and future
13. Modification of the hydroxy lactone ring of camptothecin: Inhibition of mammalian topoisomerase I and biological activity
14. Homocamptothecin, an E-ring modified camptothecin analogue, generates new topoisomerase I-mediated DNA breaks
15. Homocamptothecin, an E-ring modified camptothecin with enhanced lactone stability, retains topoisomerase I-targeted activity and antitumor properties
16. Homocamptothecins: Synthesis and antitumor activity of novel E-ring-modified camptothecin analogues
17. Synthesis of water-soluble (aminoalkyl)camptothecin analogues: Inhibition of topoisomerase I and antitumor activity
18. Synthesis and antitumor activity of 20(S)-camptothecin derivatives: Carbamate-linked, water-soluble derivatives of 7-ethyl-10-hydroxycamptothecin
19. Ultraviolet-induced DNA damage stimulates topoisomerase I DNA complex formation in vivo: Possible relationship with DNA repair
20. Characterization of PicoGreen reagent and development of a fluorescence-based solution assay for double-stranded DNA quantitation
21. Digital morphonuclear analyses of sensitive versus resistant neoplastic cells to vinca-alkaloid, alkylating, and intercalating drugs
22. Flow cytometric monitoring of anthracycline accumulation after anti-neoplastic ether phospholipid treatment
23. Technetium-99m-sestamibi uptake by human benign and malignant breast tumor cells: Correlation with mdr gene expression
24. Expression of the multidrug resistance-associated protein (MRP) mRNA and protein in normal peripheral blood and bone marrow haemopoietic cells
25. Simple and versatile high-performance liquid chromatographic method for the simultaneous quantitation of the lactone and carboxylate forms of camptothecin anticancer drugs
26. Phase II trial of CPT-11 in patients with advanced pancreatic cancer, an EORTC early clinical trials group study
27. Cellular resistance to topoisomerase-targeted drugs: From drug uptake to cell death
28. Topoisomerase I inhibitors and drug resistance
29. Efficacy and toxicity of irinotecan in patients with colorectal cancer
30. Topotecan: An oncologist's view
31. Anti-tumor activity of CPT-11 in experimental human ovarian cancer and human soft-tissue sarcoma
32. Homocamptothecin, an E-ring-modified camptothecin, exerts more potent antiproliferative activity than other topoisomerase I inhibitors in human colon cancers obtained from surgery and maintained in vitro under histotypical culture conditions
33. Mechanisms of altered sequestration and efflux of chemotherapeutic drugs by multidrug-resistant cells
34. Multidrug resistance-associated protein subfamily transporters and drug resistance
35. Recent progress in P-glycoprotein research
36. Pharmacokinetics and oral bioavailability of BN 80915, a novel topoisomerase I inhibitor, after single dose administration in rats
37. Dog pharmacokinetics and oral bioavailability of BN 80915, a novel topoisomerase I inhibitor
38. Preliminary pharmacologic and clinical evaluation of camptothecin sodium
39. Camptothecins: A review of their development and schedules of administration
40. Studies of the efficacy and pharmacology of irinotecan against human colon tumor xenograft models
41. Patient preferences for oral versus intravenous palliative chemotherapy
42. Oral chemotherapy: Rationale and future directions